Ives DV et al. |
Impact of clarithromycin and azithromycin on patterns of treatment and survival among AIDS patients with disseminated Mycobacterium avium complex. |
1995 |
AIDS |
pmid:7755914
|
Fichtenbaum CJ et al. |
Reply to 'Possible bias of ascertainment in assessing chemoprophylaxis for cryptosporidiosis' by Holmberg and Moorman. |
2001 |
AIDS |
pmid:11546956
|
Holmberg SD and Moorman AC |
Possible bias of ascertainment in assessing chemoprophylaxis for cryptosporidiosis. |
2001 |
AIDS |
pmid:11504998
|
MacÃas J et al. |
Rhodococcus or mycobacterium? An example of misdiagnosis in HIV infection. |
1997 |
AIDS |
pmid:9030376
|
Hewitt RG et al. |
Prevention of disseminated Mycobacterium avium complex infection with reduced dose clarithromycin in patients with advanced HIV disease. |
1999 |
AIDS |
pmid:10449290
|
Bayoumi AM and Redelmeier DA |
Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. |
1998 |
AIDS |
pmid:9727572
|
Burman WJ et al. |
Long-term outcomes of treatment of Mycobacterium avium complex bacteremia using a clarithromycin-containing regimen. |
1998 |
AIDS |
pmid:9708410
|
Fichtenbaum CJ et al. |
Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. |
2000 |
AIDS |
pmid:11153670
|
|
High-dose clarithromycin should be avoided. |
1996 |
AIDS Alert |
pmid:11363723
|
|
Physician's aggressive preventive therapy differs. |
1995 |
AIDS Alert |
pmid:11362774
|
|
New drug applications sought. |
1995 |
AIDS Alert |
pmid:11362777
|
|
Researchers find new drugs to fight MAC. |
1995 |
AIDS Alert |
pmid:11362925
|
|
Clarithromycin for MAC. |
1995 |
AIDS Patient Care |
pmid:11361361
|
Rosales CM et al. |
AIDS presenting with cutaneous Kaposi's sarcoma and bacillary angiomatosis in the bone marrow mimicking Kaposi's sarcoma. |
2002 |
AIDS Patient Care STDS |
pmid:12542930
|
Mah Ming JB and Gill MJ |
Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. |
2003 |
AIDS Patient Care STDS |
pmid:12816614
|
Monno R et al. |
Chlamydia trachomatis and Mycobacterium tuberculosis lung infection in an HIV-positive homosexual man. |
2001 |
AIDS Patient Care STDS |
pmid:11788074
|
Yangco BG et al. |
Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART? |
2014 |
AIDS Patient Care STDS |
pmid:24833016
|
Desimone JA et al. |
Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals. |
2003 |
AIDS Patient Care STDS |
pmid:14746655
|
|
NIAID study rules out high-dose clarithromycin for AIDS-related MAC. |
1996 |
AIDS Patient Care STDS |
pmid:11361534
|
|
New data suggest antibiotic clarithromycin is effective in prolonging life of AIDS patients. |
1996 |
AIDS Patient Care STDS |
pmid:11361575
|
|
Clarithromycin and MAC. |
1996 |
AIDS Patient Care STDS |
pmid:11361673
|
|
Different clarithromycin doses affect mortality. |
1997 |
AIDS Patient Care STDS |
pmid:11361754
|
Aboulafia DM |
Thalidomide-based treatment for HIV-associated multiple myeloma: a case report. |
2003 |
AIDS Read |
pmid:14524324
|
Kahlon SS et al. |
Mycobacterium-avium-intracellulare complex immune reconstitution inflammatory syndrome in HIV/AIDS presenting as osteomyelitis. |
2008 |
AIDS Read |
pmid:18975441
|
Chu J et al. |
Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. |
2011 |
AIDS Res Ther |
pmid:21388558
|
Smibert OC et al. |
Short Communication: Mycobacterium avium Complex Infection and Immune Reconstitution Inflammatory Syndrome Remain a Challenge in the Era of Effective Antiretroviral Therapy. |
2017 |
AIDS Res. Hum. Retroviruses |
pmid:28791872
|
Kihira K et al. |
Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930904
|
Kamada T et al. |
Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930905
|
Savarino V et al. |
OAM for cure of Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930908
|
Perri F et al. |
Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421877
|
Perri F et al. |
Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421878
|
Pilotto A et al. |
Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421879
|
Tepes B et al. |
Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer? |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421880
|
Calvet X et al. |
What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421884
|
Huang J et al. |
Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. |
2013 |
Aliment. Pharmacol. Ther. |
pmid:24117692
|
Molina-Infante J et al. |
Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. |
2010 |
Aliment. Pharmacol. Ther. |
pmid:20180787
|
Chacko Y and Holtmann GJ |
Helicobacter pylori eradication and weight gain: has it opened a Pandora's box? |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21679208
|
Nseir W et al. |
Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study. |
2012 |
Aliment. Pharmacol. Ther. |
pmid:22646167
|
Zullo A et al. |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15948808
|
Harb AH et al. |
Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:26011564
|
Veldhuyzen Van Zanten S et al. |
One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12786632
|
Nagahara A et al. |
Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11207518
|
Bardhan KD et al. |
Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632646
|
Cammarota G et al. |
Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632648
|
Gasbarrini A et al. |
Efficacy of a multistep strategy for Helicobacter pylori eradication. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632649
|
Chan FK et al. |
Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632651
|
Khurana R et al. |
Meta-analysis: Helicobacter pylori eradication treatment efficacy in children. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17305754
|
Pipkin GA et al. |
Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9768524
|
Louw JA et al. |
Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9768531
|
Laine L et al. |
Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9768532
|
Tomita T et al. |
Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966543
|
Axon AT et al. |
Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9042977
|
Labenz J et al. |
One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9042978
|
Labenz J et al. |
Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9042979
|
Calvet X et al. |
One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12144575
|
Di Caro S et al. |
Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876707
|
Wu JC et al. |
Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876709
|
Basset C et al. |
Helicobacter pylori infection: anything new should we know? |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15335411
|
Mason J et al. |
The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876711
|
Georgopoulos SD et al. |
Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876712
|
Elizalde JI et al. |
Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876713
|
Savarino V et al. |
Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:9892878
|
Spinzi GC et al. |
Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9663722
|
Bazzoli F et al. |
Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9663723
|
Pozzato P et al. |
Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9663724
|
Goh KL et al. |
Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection? |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9663838
|
Goddard AF et al. |
Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10233187
|
Kolkman JJ et al. |
Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9663840
|
Pilotto A et al. |
The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10233191
|
Miyaji H et al. |
Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9663841
|
Wong BC et al. |
Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11069326
|
Lionetti E et al. |
Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:17032283
|
Iijima K et al. |
Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15153171
|
Laurent J et al. |
A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11683693
|
O'Connor HJ et al. |
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9570262
|
Scott BB |
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9570263
|
Goodgame RW et al. |
Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11736715
|
Sheu BS et al. |
The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12755841
|
Gudjonsson H et al. |
High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9845401
|
De Francesco V et al. |
Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15113366
|
Koivisto TT et al. |
Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15113368
|
Gisbert JP and Calvet X |
Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:22017749
|
Cammarota G et al. |
High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15043520
|
Pellegrini M et al. |
Is a long-term ranitidine-based triple therapy against Helicobacter pylori only a heritage of the past? A prospective, randomized clinicopharmacological study. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:16098001
|
Huang J and Hunt RH |
Clarithromycin-based triple therapies. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10102978
|
Osato MS et al. |
Comparative efficacy of new investigational agents against Helicobacter pylori. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11284777
|
Mason JM et al. |
Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18793340
|
Fraser AG |
Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28776748
|
Jung YS et al. |
Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28776746
|
Sheu BS et al. |
Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15691303
|
Wong WM et al. |
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16423001
|
Klok RM et al. |
Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966514
|
Tsuzuki T et al. |
Clarithromycin increases the release of heat shock protein B from Helicobacter pylori. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966545
|
Gisbert JP et al. |
Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:16268980
|
Ellenrieder V et al. |
Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9701524
|
Miwa H et al. |
Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12823158
|
Lim AG et al. |
Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9218079
|
Zullo A et al. |
Clarithromycin or levofloxacin in the sequential therapy for H. pylori eradication? |
2010 |
Aliment. Pharmacol. Ther. |
pmid:20518756
|
Armuzzi A et al. |
The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11148433
|
Mégraud F and Lamouliatte H |
Review article: the treatment of refractory Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12786627
|